Publisher
Springer Science and Business Media LLC
Subject
Health, Toxicology and Mutagenesis,Toxicology
Reference10 articles.
1. Sindelar M, McCabe D, Carroll E. Tacrolimus drug-drug interaction with nirmatrelvir/ritonavir (Paxlovid™) managed with phenytoin. J Med Toxicol. 2023;19(1):45–8. https://doi.org/10.1007/s13181-022-00922-2.
2. Ko Y, Malone DC, Skrepnek GH, et al. Prescribers’ knowledge of and sources of information for potential drug-drug interactions. Drug-Safety. 2008;31:525–36. https://doi.org/10.2165/00002018-200831060-00007.
3. Ko Y, Malone DC, D’Agostino JV, et al. Potential determinants of prescribers’ drug-drug interaction knowledge. Res Social Adm Pharm. 2008;4:355–66. https://doi.org/10.1016/j.sapharm.2007.10.004.
4. Yuan J, Shen C, Wang C, et al. Assessment of physician’s knowledge of potential drug-drug interactions: an online survey in China. Front Med (Lausanne). 2021;8:650369. https://doi.org/10.3389/fmed.2021.650369.
5. National Institutes of Health (NIH). Drug-drug interactions between ritonavir-boosted nirmatrelvir (Paxlovid) and concomitant medications. Available at: https://www.covid19treatmentguidelines.nih.gov/therapies/antivirals-including-antibody-products/ritonavir-boosted-nirmatrelvir--paxlovid-/paxlovid-drug-drug-interactions/. Accessed 28 February 2023.